10-K: Spectral AI Reports Mixed 2025 Results Amid DeepView Progress

Spectral AI, an AI medical diagnostics company, reported a reduced net loss in 2025 but a decline in revenue, while advancing its DeepView System towards commercialization with key regulatory approvals and significant government funding.

Summary

• Spectral AI is an AI company focused on predictive medical diagnostics, primarily developing the DeepView System for burn wound healing assessment.
• The DeepView System uses proprietary AI algorithms and multispectral imaging to differentiate between healing and non-healing tissue, providing a Day One assessment.
• The company received UKCA marking for its DeepView System for burn indications on February 22, 2024, with registration completed on March 7, 2024, anticipating initial UK sales in 2026.
• A De Novo application for Class II medical device designation with the U.S. FDA was submitted in June 2025, with a target for approval in 2026.
• Since 2013, Spectral AI has been awarded approximately $282.5 million in government funding, with $272.9 million from BARDA.
• A new BARDA contract, executed September 27, 2023, provides up to $150.0 million in additional funding, including an initial award of $54.9 million for clinical validation and FDA clearance.
• The company reported a net loss of $7.5 million for the year ended December 31, 2025, an improvement from a $15.1 million net loss in 2024.
• Research and development revenue decreased by 33.6% to $19.65 million in 2025 from $29.58 million in 2024, primarily due to decreased work under the BARDA contract's base phase.
• Cash and cash equivalents increased to $15.4 million as of December 31, 2025, from $5.1 million in 2024, largely due to financing activities.
• Material weaknesses in internal control over financial reporting were identified related to complex equity arrangements, financial statement close process, accruals, and unbilled revenue.
• The company is developing additional DeepView programs, including the handheld DeepView SnapShot M for military and emergency care, and 3D wound measurement technology.
• Strategic partnerships with medical institutions and healthcare providers in the U.S. and Europe are in place, including a memorandum of understanding with PolyNovo, Ltd. for Australian expansion.
• As of December 31, 2025, the company had 65 full-time employees and plans for new hires in operations, sales, marketing, and government contracts in 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive, reflecting significant progress in regulatory approvals and continued strong government funding, which de-risks development. However, the decline in R&D revenue and identified internal control weaknesses temper the enthusiasm, indicating operational challenges and continued reliance on external financing.

Positives

• Net loss significantly improved to $7.5 million in 2025 from $15.1 million in 2024.
• Cash balance increased to $15.4 million at year-end 2025, up from $5.1 million in 2024, bolstering liquidity.
• Received UKCA marking for the DeepView System for burn indications in February 2024, enabling initial sales in the UK in 2026.
• Submitted De Novo application to the FDA in June 2025 for Class II medical device designation, targeting approval in 2026.
• DeepView System validation study showed superiority in sensitivity and met non-inferiority margin in specificity compared to clinician assessment for burn wound healing.
• Secured substantial non-dilutive government funding, including a new BARDA contract up to $150.0 million (initial $54.9 million award) and MTEC grants totaling $7.2 million for the DeepView SnapShot M.
• A BARDA contract modification in March 2026 advanced $31.7 million in funding and extended the base phase of the contract.
• Named to TIME's Worlds Top HealthTech Companies 2025 list, enhancing market recognition.
• Proprietary and clinically validated database of over 340 billion pixels of image data creates a significant barrier to entry for competitors.
• Established strategic partnerships with leading research hospitals and key opinion leaders in the U.S. and Europe, and expanded into Australia via PolyNovo, Ltd.

Negatives

• Research and development revenue decreased by 33.6% to $19.65 million in 2025 from $29.58 million in 2024, indicating reduced activity on existing contracts.
• The company has incurred significant losses since inception, with an accumulated deficit of $55.8 million as of December 31, 2025.
• Highly dependent on government funding, primarily from BARDA and DHA, with no commercial sales revenue generated to date.
• Regulatory review process is expensive, time-consuming, and uncertain; FDA clearance for the DeepView System is not guaranteed and may be delayed.
• Identified material weaknesses in internal control over financial reporting related to complex equity arrangements, financial statement close process, accruals, and unbilled revenue.
• The company's ability to raise additional capital on favorable terms or at all is not assured, which could impact business plan execution and product development.
• Warrants may become exercisable, increasing shares eligible for resale and potentially diluting existing stockholders.
• The company has no experience in marketing and selling its DeepView System commercially and needs to build out sales and marketing capabilities.

Risks

• Incurred significant losses since inception and may not achieve significant revenues or profitability.
• Dependence on government funding, particularly from BARDA, which is not guaranteed to be fully awarded or extended, could materially adversely affect research and development and commercialization efforts.
• The regulatory review process (FDA clearance, De Novo classification, UKCA, CE Mark) is expensive, time-consuming, and uncertain, potentially delaying product launch.
• Significant delays in completing clinical trials could prevent or delay targeted product launch timeframe and impair viability.
• New legislation and regulations for medical devices and AI technology could increase costs and difficulty in obtaining regulatory approvals or commercializing products.
• Disruptions at regulatory agencies (FDA, foreign bodies) due to funding shortages or global health concerns could hinder timely product development and commercialization.
• Modifications to the DeepView System may require new regulatory clearances, potentially halting marketing or requiring recalls.
• Quality problems and product liability claims could lead to recalls, reputational harm, costly settlements, and increased insurance rates.
• Failure to comply with anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations could result in significant penalties.
• Reliance on third-party manufacturers and single/sole source suppliers makes the company vulnerable to supply shortages and price fluctuations.
• Difficulties in managing anticipated growth, including expanding operations and recruiting/training personnel, could disrupt operations.
• High dependence on senior management and key personnel; inability to attract and retain them could harm the business.
• The use of artificial intelligence, including machine learning, in analytics platforms may result in reputational harm or liability due to flawed algorithms, insufficient data, or ethical concerns.
• The success of algorithms depends on a significant repository of proprietary burn image and data; loss of access to this data would be materially adverse.
• Changes in patent law or its interpretation could diminish the value of patents, impairing the ability to protect existing and future products.
• Patent rights and other intellectual property may be subject to priority, ownership, or inventorship disputes, interferences, and similar proceedings, limiting enforcement.
• Nasdaq may delist securities if certain price or market capitalization levels are not maintained, limiting investor transactions and liquidity.
• The price of Common Stock and Warrants may be volatile due to various market and company-specific factors.
• Failure to maintain proper and effective internal controls over financial reporting could impair the ability to produce accurate and timely financial statements and lead to investor loss of confidence.
• Existing stockholders purchased securities at prices below current trading, and future investors may not experience similar returns.
• Exercise of warrants would increase the number of shares eligible for resale and result in dilution to stockholders.
• Cybersecurity risks, including attacks and data breaches, could materially and adversely affect business, financial condition, and reputation.
• International expansion exposes the company to market, regulatory, political, operational, financial, and economic risks.
• Contracts with BARDA and DHA grant the U.S. government certain rights in inventions and data developed under the contracts, potentially affecting intellectual property rights.

Future Outlook

Spectral AI anticipates commencing initial commercial sales of its DeepView System in the UK in 2026, following UKCA authorization. The company expects to achieve Class II medical device designation with the U.S. FDA in 2026 via its De Novo application, with commercialization in the United States also expected to initiate during 2026, aligned with the BARDA contract timeline. Future revenue streams are projected to include a SaaS model for software licensing and sales of the imaging device. The company plans to expand its sales and marketing teams and hire additional personnel in operations, sales, marketing, and government contracts in 2026 to support commercialization and growth. Further development of DeepView SnapShot M and 3D wound measurement technology is ongoing, with potential for additional clinical indications and international expansion into the EU and Middle East.

Management Comments

• We believe that our cash and cash equivalents, together with the remaining funding available to us under the BARDA contract, the MTEC Agreement, the Avenue Financing, the Yorkville SEPA and other financings completed by the Company will be sufficient to meet our capital requirements and fund our operations through at least the next 12 months from the release date of the consolidated financial statements.
• We believe that our DeepView System will allow clinicians to make more accurate and efficient treatment decisions in the wound care sector.
• We believe that educating notable industry key opinion leaders and clinicians about the merits and benefits of our DeepView System, including safety, performance, ease of use and efficiency will be critical for increasing the adoption of our device.
• We believe that our strategic partnerships with various leading medical institutions and healthcare providers in the United States and Europe will enable us to access high quality image data and build the worlds leading wound biopsy tissue database.
• Our AI algorithms are designed and trained to the clinical ground truth that has been verified and vetted by various U.S. government agencies and leading clinicians in their respective fields.

Industry Context

StockSavvy.ai notes that Spectral AI operates in the rapidly evolving medical diagnostics sector, leveraging AI and multispectral imaging to address a significant unmet clinical need in wound care, particularly burn assessment. The company's focus on objective, Day One healing predictions positions it uniquely against traditional subjective clinician assessments. Its substantial government funding from agencies like BARDA and DHA highlights the strategic importance of its technology for public health and military applications, providing a stable, non-dilutive revenue base uncommon for pre-commercialization medical device companies. The pursuit of both UKCA and FDA De Novo approvals reflects a strategic multi-market approach, while the development of handheld devices and 3D measurement technology aligns with broader industry trends towards portability, precision, and enhanced diagnostic capabilities. The identified material weaknesses in internal controls, however, are a common challenge for growing companies transitioning to public reporting, and their remediation will be crucial for investor confidence and operational maturity.

Comparison to Industry Standards

• DeepView System's Day One assessment of wound healing potential significantly improves upon the current standard of care, which typically involves subjective clinician assessment and weeks of observation.
• The DeepView System has shown superiority in sensitivity and met non-inferiority margin in specificity compared to clinician assessment in its validation study, indicating a higher diagnostic accuracy than burn physicians assessing the same population.
• To our knowledge, there are no comparable digital wound healing predictive medical diagnostic products that provide clinicians with an objective and immediate assessment of a wound's future healing potential that benefit from the application of AI.
• Unlike many existing wound imaging systems that primarily provide physiological data or documentation tools, DeepView translates raw physiological data into a binary healing vs. non-healing prediction, offering a direct clinical answer.
• The proprietary and clinically validated database of over 340 billion pixels of image data for burns presents a significant barrier to entry for would-be competitors in wound care healing assessment, distinguishing Spectral AI from other players who might rely on less controlled or smaller datasets.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is not a party to any material legal proceedings or pending claims.
• The Company is aware of a material threatened claim that it believes is without merit.
• From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities, none of which are believed to be material or expected to have a material adverse effect.

Related Party Transactions

• On March 19, 2024, Spectral IP (a wholly-owned subsidiary) received a $1.0 million investment from an affiliate of the company's largest shareholder, structured as a note payable.
• The Spectral IP Note was amended on October 1, 2024, to reduce the interest rate from 8% to 4%, extend the term, and include a conversion feature.
• The holder of the Spectral IP Note converted the full outstanding principal and interest into 540,996 shares of the company's Common Stock during Q4 2024.
• On May 5, 2025, the company entered into an intellectual property license agreement with Spectral IP, granting a worldwide, non-exclusive license to one international patent asset for commercialization outside the company's core focus areas on market terms to be finalized.

Stakeholder Impact

• **Shareholders:** Potential for dilution from warrant exercises and future equity raises. Improved net loss and progress towards commercialization could positively impact share price, but revenue decline and internal control weaknesses pose risks.
• **Employees:** Continued workforce expansion and competitive compensation/benefits packages aim to attract and retain talent. Insider trading policy provides clear guidelines for securities transactions.
• **Customers (Healthcare Professionals/Institutions):** DeepView System aims to provide more accurate, timely, and objective burn wound assessments, potentially improving patient outcomes and reducing hospital stays/costs. UKCA marking and anticipated FDA approval will expand access.
• **Government Agencies (BARDA, DHA, MTEC):** Continued partnership and funding from these agencies validate the technology and support its development for public health and military applications.
• **Suppliers/Contract Manufacturers:** Continued reliance on third-party manufacturers like Cobalt Product Solutions, creating ongoing business for them but also exposing the company to supply chain risks.

Next Steps

• Initiate commercial sales of the DeepView System in the UK in 2026.
• Obtain Class II medical device designation from the U.S. FDA for the DeepView System in 2026.
• Initiate commercialization in the United States during 2026, in accordance with the projected timeline for the BARDA contract.
• Complete the remaining phases of the BARDA PBS contract, supporting the long-term goal of entering a federal procurement contract.
• Conduct health economic and outcome research to support broader clinical adoption of the DeepView System.
• Continue development of DeepView SnapShot M, with the MTEC contract extended through June 2026.
• Continue development of 3D wound measurement technology for integration into the DeepView System.
• Partner with U.S. governmental agency sponsors to implement distribution of the DeepView System in key regions to support mass casualty countermeasure directives.
• Expand sales and marketing teams and hire additional personnel in operations, sales, marketing, and government contracts in 2026 and beyond.
• Leverage U.S. study results for simultaneous conformity assessment procedure in the EU to obtain CE marking.
• Commence post-market studies in the UK.
• Apply for CPT codes for DeepView System reimbursement in the United States as clinical evidence and utilization increase.
• Remediate identified material weaknesses in internal control over financial reporting by formalizing processes, strengthening supervisory reviews, engaging financial consultants, and enhancing ERP system functionality.

Key Dates

Recommendation

Spectral AI presents a mixed financial picture with a reduced net loss but declining revenue, indicating a company in a critical transition phase from R&D to commercialization. The significant government funding and recent UKCA approval are strong positives, de-risking development and opening new markets. However, the identified material weaknesses in internal controls and the continued dependence on external financing for growth introduce notable risks. FDA approval, while anticipated in 2026, is not guaranteed and is a major catalyst. Given the promising technology and regulatory progress balanced against operational challenges and financial reliance, a 'hold' recommendation is appropriate. Investors should monitor FDA approval, commercialization progress in the UK and US, and the successful remediation of internal control weaknesses before considering further investment.

Keywords

AI medical diagnostics, DeepView System, Burn wound healing, Multispectral imaging, FDA De Novo, UKCA marking, BARDA funding, Government contracts, Medical device, Artificial intelligence, Healthcare technology, Clinical trials, SaaS model, DeepView SnapShot M, 3D wound measurement, Intellectual property, Financial reporting, Nasdaq